Expression Of C-MYC And MDM2 Protein In Multiple Myeloma And Their Correlation With Clinical Stage

Background and ObjectiveMultiple Myeloma(MM) is a malignant tumor that originates from monoclonal plasma cells which exists in marrow B lymphocyte, which is the most common lymphatic hematopoietic system tumor that may occur in bones. The pathogenesis of Multiple Myeloma is not clear, and especially for the fact that the higher the clinical stage, the worse the prognosis, so it cannot be cured. Based on the facts above, the research is focusing on some fileds now, including the discussion about the development mechanism of the multiple myeloma, the search of possible targets of the clinical treatment, and prognosis judgement index.C-myc gene, which is closely related to cell cycle regulation, is a member of the MYC oncogene family.The abnormal expression of C-myc gene plays a very important role in regulating cell malignant transformation, growth and differentiation. The research shows that the amplification or over-expression of C-myc gene can be found in a few kinds of cancers, like breast cancer, stomach cancer, colon cancer, head and neck cancer,lymphoma etc.MDM2 is a proto-oncogene,which initially is a highly amplified gene cloned from fibroblasts in mice that includes double minute, MDM2 can accelerate the cellular conversion from G1 to S by activating E2F-1 and it also can regulate cell proliferation and apoptosis by restraining the function of wild-type P53. MDM2 have a close relationship with the development of numerous malignant tumors, such as soft tissue sarcoma, osteosarcoma and glioma, etc, so targeting on the C-myc or MDM2 and its related gene may become a effective curing method.The expression of C-myc protein or MDM2 protein are rarely found in the report about multiple myeloma, and joint detection the expression of C-myc protein and MDM2 protein in multiple myeloma is not appeared in existed reports till now. This research applied immunohistochemical on testing the expression of MDM2 protein and C-myc Protein in different clinical stages of multiple myeloma and nontumorous bone marrow tissue for understanding the relationship between its significance in the occurrence and development of multiple myeloma and clinical stage. Methods1.Apply immunohistochemical SP-9000 three steps method to test the expression of MDM2 protein and C-myc protein in different clinical stages of multiple myeloma and nontumorous bone marrow tissue.2.Statistical analysis: the data was analyzed by SPSS21.0 software,the count data was analyzed by chi-square test,correlation analysis by Spearman rank correlation analysis.Inspection level of ?=0.05. Results1.The positive rate of C-myc and MDM2 protein in multiple myelom were 71.7% and 80.0% respectively, the positive rate of C-myc and MDM2 protein in nontumorous bone marrow tissue were 10% and 20% respectively. The difference was statistically significant(P < 0.05).2.The expression of C-myc protein and MDM2 protein was positively correlated with multiple myeloma clinical ISS stage(P < 0.05), but irrelevant with the age and gender(P>0.05).3.The expression of C-myc and MDM2 protein in Multiple myeloma was positively correlation(P < 0.05). Conclusions1.The over-expression of C-myc protein and MDM2 protein in MM may be relative to the occurrence of multiple myeloma and clinical stage, but irrelevant with the age and gender of patients.2. In multiple myeloma, C-myc protein and MDM2 protein may have synergetic functions and promote the development of tumor together.